EJHaem
Modified Newcastle Regimen Improves Survival Despite Central Nervous System Relapse in Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
By Suh M, Cho H, Go H and 13 others.
Abstract
Background
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare, aggressive malignancy with a median overall survival (OS) of 7-15 months. The Newcastle regimen, comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), ifosfamide, etoposide, and epirubicin (IVE), and intermediate-dose methotrexate for central nervous system (CNS) prophylaxis, has demonstrated promising outcomes in enteropathy-associated T-cell lymphoma (EATL) but has not been evaluated in MEITL, where the CNS relapse risk informing methotrexate use remains poorly characterized.
